Priscilla Chan argues that conditions like hypertension are treated by trial and error because we lump diverse individual biologies together. The goal is to move beyond demographics to a precise, individual-level understanding. By connecting genetic variants to protein expression, every disease treatment becomes effectively personalized, as if it were a "rare" disease.

Instead of only seeking disease-causing genes, Regeneron's primary strategy is to find rare protective mutations in individuals they call "superhumans." These people, naturally protected from diseases like heart attacks, provide a validated blueprint for new drugs. The company has already found over 50 such protective factors.

Genomics (DNA/RNA) only provides the 'sheet music' for cancer. Functional Precision Medicine acts as the orchestra, testing how live tumor cells respond to drugs in real time. AI serves as the conductor, optimizing the 'performance' for superior outcomes.

The highly personalized, N-of-1 approaches developed for rare diseases are not a niche field. With advanced genetic sequencing, it's becoming clear that every disease is effectively rare and unique to the individual. The lessons from rare disease are creating the foundation for all future medicine.

Instead of targeting rare, single-gene mutations, Medera's therapy restores a protein universally downregulated in most forms of heart failure. This "umbrella pathway" strategy allows a single drug to treat multiple cardiac diseases, whether genetic or acquired, dramatically expanding the potential patient population from rare to common diseases.

The ultimate vision is to move beyond generalized treatments to truly individualized medicine. This involves understanding the complete causal chain from a person's unique genetic variants to the resulting protein behavior and disease. With this mechanistic understanding, it becomes possible to design a bespoke drug for that specific individual.

By injecting gene therapy directly into the heart, Medera bypasses systemic circulation. This allows for a 100x lower dose than traditional IV methods, which eliminates the need for immunosuppressants, reduces severe adverse events, and significantly lowers manufacturing costs, making gene therapy for common diseases commercially viable.

The primary bottleneck in drug development isn't creating therapies but identifying the right targets. Regeneron built its massive genetics database to find rare, protective genetic mutations in humans, effectively de-risking the target identification process and aiming to improve the industry's low success rate.

Many diseases have well-understood genetic causes but lack effective treatments. Genesis CEO Evan Feinberg argues this makes drug discovery the most impactful area for AI, as it directly addresses the bottleneck of creating selective therapies for known targets where no medicine currently exists.